Core Viewpoint - Fuhong Hanlin's stock price surged over 8%, reaching a historical high of 89 HKD, and currently stands at 85.55 HKD with a trading volume of 99.13 million HKD, following the announcement of the first prescription for its innovative small molecule CDK4/6 inhibitor, Fuzhoning [1] Group 1 - Fuhong Hanlin announced that its small molecule CDK4/6 inhibitor, Fuzhoning (Citrus Acid Vovisil Capsules), has received its first prescription from over ten hospitals across China, including Fudan University Shanghai Cancer Center and Zhejiang University School of Medicine First Affiliated Hospital [1] - Fuzhoning, in combination with Fulvestrant, is indicated for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) recurrent or metastatic breast cancer patients who have experienced disease progression after prior endocrine therapy [1] - The drug is owned by Jinjou Aohong Pharmaceutical, a subsidiary of Fosun Pharma, while Fuhong Hanlin is responsible for its commercialization in China [1]

消息面上，复宏汉霖公布，旗下创新型小分子CDK4/6抑制剂复妥宁(枸橼酸伏维西利胶囊)的首张处 方，近日由复旦大学附属肿瘤医院、中国医学科学院肿瘤医院、浙江大学医学院附属第一医院、安徽医 科大学附属第一医院、山东省肿瘤医院、上海市第十人民医院、南京鼓楼医院及青岛大学附属医院等十 多家医院，在全国各地陆续开出。 据悉，复妥宁联合氟维司群可用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮 生长因数2(HER2)阴性的复发或转移性成年乳腺癌患者。复宏汉霖表示，该药物由复星医药成员企业锦 州奥鸿药业拥有自主智慧财产权，其在中国的商业化推广由复宏汉霖负责。 智通财经APP获悉，复宏汉霖(02696)涨超8%，高见89港元再创历史新高，截至发稿，涨5.31%，报86.2 港元，成交额7364.75万港元。 ...

据悉，复妥宁联合氟维司群可用于既往接受内分泌治疗后出现疾病进展的激素受体(HR)阳性、人表皮 生长因数2(HER2)阴性的复发或转移性成年乳腺癌患者。复宏汉霖表示，该药物由复星医药（600196） 成员企业锦州奥鸿药业拥有自主智慧财产权，其在中国的商业化推广由复宏汉霖负责。 消息面上，复宏汉霖公布，旗下创新型小分子CDK4/6抑制剂复妥宁(枸橼酸伏维西利胶囊)的首张处 方，近日由复旦大学附属肿瘤医院、中国医学科学院肿瘤医院、浙江大学医学院附属第一医院、安徽医 科大学附属第一医院、山东省肿瘤医院、上海市第十人民医院、南京鼓楼医院及青岛大学附属医院等十 多家医院，在全国各地陆续开出。 复宏汉霖(02696)涨超8%，高见89港元再创历史新高，截至发稿，涨5.31%，报86.2港元，成交额 7364.75万港元。 ...

Core Viewpoint - Fosun Pharma reported a slight decline in revenue but a significant increase in net profit, indicating a strong performance in innovation and strategic development [1] Financial Performance - In the first half of 2025, Fosun Pharma achieved revenue of 19.514 billion yuan, a year-on-year decrease of 4.63% - The net profit attributable to shareholders reached 1.702 billion yuan, reflecting a year-on-year growth of 38.96% - Revenue from innovative drugs exceeded 4.3 billion yuan, marking a year-on-year increase of 14.26% [1] Innovation and R&D - Fosun Pharma invested 2.584 billion yuan in R&D during the first half of 2025 - The company is focusing on core therapeutic areas such as solid tumors, hematological tumors, and immune inflammation, while also exploring chronic diseases and neurological fields [1][2] Product Development - In the solid tumor sector, Fosun Pharma has developed a matrix of innovative drugs, including the approval of a new small molecule CDK4/6 inhibitor and a first self-developed small molecule drug for dual indications - The CAR-T product, Yikaida, is being promoted for accessibility and affordability, with inclusion in over 110 health insurance plans [2] Global Market Expansion - Fosun Pharma's overseas revenue reached 5.478 billion yuan, accounting for approximately 28.07% of total revenue - The company is enhancing its global business development through licensing and collaboration, focusing on unmet clinical needs [3] Sustainability and ESG - Fosun Pharma has improved its MSCI ESG rating to AA, reflecting its commitment to sustainable development [3]

Core Viewpoint - Shanghai Fosun Pharmaceutical Group Co., Ltd. reported a decrease in revenue but an increase in net profit for the first half of 2025, indicating a focus on innovation and operational efficiency despite challenges in the pharmaceutical market [4][5][6]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately CNY 19.51 billion, a decrease of 4.63% compared to the same period last year [4]. - Total profit for the period was approximately CNY 2.72 billion, reflecting a 40.77% increase year-on-year [4]. - Net profit attributable to shareholders was approximately CNY 1.70 billion, up 38.96% from the previous year [4]. - The net cash flow from operating activities increased by 11.90% to approximately CNY 2.13 billion [4]. Business Overview - The company operates in pharmaceuticals, medical devices, and healthcare services, with a focus on innovative drugs and high-value medical equipment [6][7]. - The pharmaceutical segment remains the core business, emphasizing the development of innovative drugs targeting various diseases [6][7]. - The company has established a comprehensive manufacturing system, with all domestic production lines certified by GMP [7]. Industry Context - The Chinese pharmaceutical industry is undergoing a transformation towards high-quality development, supported by government policies aimed at fostering innovation [6][10]. - The market for medical devices is expanding due to policies promoting equipment updates and compliance with international standards [10]. - The healthcare sector is experiencing growth driven by an aging population and increasing demand for chronic disease management [6][10]. Innovation and R&D - The company is committed to developing "Best-in-class" and "First-in-class" products, with several innovative drugs approved for the Chinese market [11][12]. - The introduction of CAR-T cell therapy and other advanced treatments highlights the company's focus on cutting-edge medical solutions [12]. - The company has also made strides in AI, being recognized for its PharmAID decision-making platform [13]. Market Position - Shanghai Fosun Pharmaceutical ranked 5th in the 2024 China Pharmaceutical Industry Top 100 list, indicating a strong market presence [13]. - The company is actively expanding its international footprint, particularly in emerging markets [8][9]. ESG and Compliance - The company has joined the Pharmaceutical Supply Chain Initiative (PSCI) to enhance supply chain responsibility and align with international standards [13]. - It has received an upgraded MSCI ESG rating of AA, reflecting its commitment to environmental, social, and governance practices [13].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《2025 年半年度報告》，僅供參閱。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年8 月2 6 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執 行董事為陳啟宇先生、潘東輝先生及吳以芳先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、 Chen Penghui先生及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 ...